In the current study, dorzagliatin alone improved the impaired glucose-stimulated GLP-1 secretion in patients with T2D and obesity with an iCmax of GLP-1total reached 22.10 pmol/L (~27 pmmol/L in Cmax, Supplementary Fig. S4), approaching to the healthy range of maximum GLP-1 level described above. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.